{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Singla A"],"funding":["Division of Chemistry","National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","Men of Distinction"],"pagination":["40724-40737"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9480101"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(36)"],"pubmed_abstract":["<i>Pseudomonas aeruginosa</i> is the leading nosocomial and community-acquired pathogen causing a plethora of acute and chronic infections. The Centers for Disease Control and Prevention has designated multidrug-resistant isolates of <i>P. aeruginosa</i> as a serious threat. A novel delivery vehicle capable of specifically targeting  <i>P. aeruginosa</i>, and encapsulating antimicrobials, may address the challenges associated with these infections. We have developed hetero-multivalent targeted liposomes functionalized with host cell glycans to increase the delivery of antibiotics to the site of infection. Previously, we have demonstrated that compared with monovalent liposomes, these hetero-multivalent liposomes bind with higher affinity to <i>P. aeruginosa</i>. Here, compared with nontarg"],"journal":["ACS applied materials & interfaces"],"pubmed_title":["Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat <i>Pseudomonas aeruginosa</i> Infections."],"pmcid":["PMC9480101"],"funding_grant_id":["CHE-1904784","R03AI139650","R21 AI149383","R21AI149383","R03 AI139650"],"pubmed_authors":["Chirra B","Cannon CL","Chen Q","Hassan AM","Shah KN","Singla A","Southerland MR","Chapman MJ","Rose RE","Gairola A","Simbassa SB","Ivanov I","Wu HJ","Sen A","Baeza J","Basharat A","Raina R"],"additional_accession":[]},"is_claimable":false,"name":"Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat <i>Pseudomonas aeruginosa</i> Infections.","description":"<i>Pseudomonas aeruginosa</i> is the leading nosocomial and community-acquired pathogen causing a plethora of acute and chronic infections. The Centers for Disease Control and Prevention has designated multidrug-resistant isolates of <i>P. aeruginosa</i> as a serious threat. A novel delivery vehicle capable of specifically targeting  <i>P. aeruginosa</i>, and encapsulating antimicrobials, may address the challenges associated with these infections. We have developed hetero-multivalent targeted liposomes functionalized with host cell glycans to increase the delivery of antibiotics to the site of infection. Previously, we have demonstrated that compared with monovalent liposomes, these hetero-multivalent liposomes bind with higher affinity to <i>P. aeruginosa</i>. Here, compared with nontarg","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T20:07:50.873Z","creation":"2025-04-04T20:07:50.873Z"},"accession":"S-EPMC9480101","cross_references":{"pubmed":["36018830"],"doi":["10.1021/acsami.2c12943"]}}